Evidence map›Paper›PMID 35830202›Full record

ArticleDrug testing and analysis2023

Key challenges for in vitro testing of tobacco products for regulatory applications: Recommendations for dosimetry.

Jacqueline Miller-Holt, Holger Behrsing, Ian Crooks, Rodger Curren, Kubilay Demir, Jeremie Gafner, Gene Gillman, Michael Hollings, Robert Leverette, Michael Oldham and 5 more

Abstract read
In one paragraph

Article in Drug testing and analysis, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Key Challenges forAlternatives to laboratory animals : ATLA · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Jacqueline Miller-HoltScientific & Regulatory Affairs, JT International SA, Geneva, Switzerland.ORCID https://orcid.org/0000-0001-5815-0552
Holger BehrsingInstitute for In Vitro Sciences, Gaithersburg, Maryland, USA.
Ian CrooksConsumer Product Safety, British American Tobacco, Southampton, UK.
Rodger CurrenInstitute for In Vitro Sciences, Gaithersburg, Maryland, USA.
Kubilay DemirRegulatory Science, JUUL Labs Inc., 1000 F Street NW, Washington D.C., 20004, USA.
Jeremie GafnerScientific & Regulatory Affairs, JT International SA, Geneva, Switzerland.
Gene GillmanRegulatory Science, JUUL Labs Inc., 1000 F Street NW, Washington D.C., 20004, USA.
Michael HollingsGenetic Toxicology, Labcorp Early Development Laboratories Ltd., Harrogate, UK.
Robert LeveretteScientific & Regulatory Affairs, RAI Services Company, Winston-Salem, North Carolina, USA.
Michael OldhamRegulatory Science, JUUL Labs Inc., 1000 F Street NW, Washington D.C., 20004, USA.
Liam SimmsGroup Science and Regulatory Affairs, Imperial Brands, Bristol, UK.
Leon F StankowskiGenetic and In Vitro Toxicology, Charles River Laboratories-Skokie, Skokie, Illinois, USA.
David ThorneConsumer Product Safety, British American Tobacco, Southampton, UK.
Roman WieczorekGroup Science and Regulatory Affairs, Reemtsma Cigarettenfabriken GmbH, an Imperial Brands PLC Company, Hamburg, Germany.
Martha M MooreMartha M Moore LLC, Little Rock, Arkansas, USA.

Funding

Workshop series to identify, discuss, and develop recommendations for the optimal generation and use of in vitro assay data for tobacco product regulation.R13FD007386 · FDA · INSTITUTE FOR IN VITRO SCIENCES, INC. · PI CURREN, RODGER D · 2021 to 2021
$50k
FDA HHS 1R13D007386FDA HHS R13 FD007386
6 · The paper itself

Abstract

The Institute for In Vitro Sciences (IIVS) is sponsoring a series of workshops to develop recommendations for optimal scientific and technical approaches for conducting in vitro assays to assess potential toxicity within and across tobacco and various next-generation products (NGPs) including heated tobacco products (HTPs) and electronic nicotine delivery systems (ENDSs). This publication was developed by a working group of the workshop members in conjunction with the sixth workshop in that series entitled "Dosimetry for conducting in vitro evaluations" and focuses on aerosol dosimetry for aerosol exposure to combustible cigarettes, HTP, and ENDS aerosolized tobacco products and summarizes the key challenges as well as documenting areas for future research.

Indexed as

Electronic Nicotine Delivery SystemsTobacco ProductsAerosolsIn Vitro TechniquesAerosolsaerosoldosimetrynext-generation products (NGPs)smoke

Identifiers

PMID35830202
PMCPMC9897201

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.